Showing results (591-600 of 667) with videos related to
Sort By:
Pageof 67
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canalP A Ott, S A Piha-Paul, P Munster, et al.American Journal of Veterinary Research|December 6, 2023
Intramuscular but not nebulized administration of a mRNA vaccine against Rhodococcus equi stimulated humoral immune responses in neonatal foalsRebecca M Legere, Cristina Poveda, Jeannine A Ott, et al.Molecular & Cellular Proteomics : MCP|August 15, 2021
Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue SamplesSusan Klaeger, Annie Apffel, Karl R Clauser, et al.Digestive Diseases and Sciences|January 18, 2006
Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled studyLuiz E Mazzoleni, Guilherme B Sander, Eduardo A Ott, et al.The Lancet. Oncology|October 14, 2016
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialPadmanee Sharma, Margaret K Callahan, Petri Bono, et al.Nature Chemical Biology|February 18, 2014
A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responsesQin Liang, Thomas S Dexheimer, Ping Zhang, et al.Immunity|February 24, 2017
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine LeiomyosarcomaSuzanne George, Diana Miao, George D Demetri, et al.Journal of Internal Medicine|August 29, 2023
Precision cancer medicine: Concepts, current practice, and future developmentsAnders Edsjö, Louise Holmquist, Birgit Geoerger, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerHope S Rugo, Jean-Pierre Delord, Seock-Ah Im, et al.Cancer|August 18, 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodiesAlain P Algazi, Katy K Tsai, Alexander N Shoushtari, et al.Pageof 67